{Reference Type}: Journal Article
{Title}: Racial and Ethnic Diversity in Vitiligo Clinical Trials: A Retrospective Cross-Sectional Study Assessing Demographic Reporting of Participants.
{Author}: Holla S;Hurtado ACM;Gonzalez S;Gupta R;Pandya AG;Elbuluk N;
{Journal}: J Drugs Dermatol
{Volume}: 23
{Issue}: 7
{Year}: 2024 Jul 1
{Factor}: 1.608
{DOI}: 10.36849/JDD.8117
{Abstract}: <B>BACKGROUND: </B>While the prevalence of vitiligo is similar across racial and ethnic groups, the effects of vitiligo vary by demographic group, culture, and skin color, with darker-skinned individuals facing greater stigma due to increased visibility of the disease.1,2 The recruitment of diverse participants that are representative of the United States (US) population is crucial to ensuring the generalizability of findings and understanding the impacts of vitiligo across diverse patient groups.&nbsp;&nbsp; Objectives: This study aimed to determine demographic reporting trends in US vitiligo clinical trials and to determine whether participants are representative of the US population.<BR><B>METHODS: </B>A search for US vitiligo clinical trials was conducted on clinicaltrials.gov. Trials conducted between 2006 to September 5, 2023, were included if they intended to treat vitiligo, were conducted in the US, and were completed or terminated.&nbsp; Results: Of the 15 trials meeting inclusion criteria, only 60% (n=9) reported participant race/ethnicity. These 9 studies included 1,510 participants, of which only 25.43% (n=384) were non-White and 20.40% were Hispanic. There was disproportionately low representation of racial minorities, particularly Black, Native American, and Native Hawaiian groups.&nbsp;&nbsp; Limitations: Limitations of our study include small sample size, variations in demographic reporting between trials, and undercounting of minority groups by the US Census.&nbsp; Conclusions: Racial and ethnic minority groups remain underrepresented in US vitiligo clinical trials. Given that the impact of vitiligo can vary by the affected individual&rsquo;s demographic group and skin color, investigators must be intentional about including a more diverse and representative population in vitiligo clinical trials.&nbsp; J Drugs Dermatol. 2024;23(7):e164-e166. doi:10.36849/JDD.8117e.